ARS Pharmaceuticals (SPRY) Q3 2026: Double Miss, Sharply Lower Costs
As seen on the 24/7 Wall St. homepage on November 5, 2026.
SG&A fell to $43.5 million from $74.8 million a year ago after ARS Pharmaceuticals killed broad consumer advertising, with both lines missing expectations and management reaffirming cash flow breakeven by the end of 2027. Neffy's US market share only moved to 5% from 4%, so the cheaper playbook has to prove it can still buy growth.
Continue ReadingShow less
ARS Pharmaceuticals reported Q3 2026 revenue of $37.71 million, missing the $41.99 million consensus by roughly 10%, while its GAAP loss of $0.36 per share came in 8% wider than the $0.33 estimate. Revenue did grow 16% year over year, but both headline lines landed below what analysts had penciled in, making this a clean double miss.
The more constructive story was on the cost side. SG&A collapsed to $43.5 million from $74.8 million a year ago after the company exited linear TV and broad consumer advertising in favor of a tighter, account-based targeting approach. That represented a 42% reduction from the first-half 2026 quarterly average, a meaningful shift in how ARS is spending its way toward commercial viability.
Buried within the per-share loss is a one-time $12.5 million license payment for exclusive worldwide rights to certain intellectual property, booked inside R&D, alongside $8.1 million in stock-based compensation. Both items are included in the GAAP figure, so the underlying loss is somewhat softer than the headline number implies, though investors will want to see whether the restructured commercial model can actually accelerate neffy's uptake.
Sponsored
Neffy's U.S. market share edged to 5% from 4% a year ago, a modest gain that raises questions about how much growth the leaner spending model can sustain. In field-targeted accounts the picture looks better, with share reaching approximately 9% versus 6% a year earlier, while non-targeted accounts sat at just 2%. Unique prescribers reached 19,605 in the quarter, up 49% year over year, which management points to as evidence that provider adoption is broadening.
Management reaffirmed its goal of reaching cash flow breakeven by the end of 2027, with second-half 2026 aggregate SG&A and R&D guidance of $114 million to $126 million, including stock-based compensation. The next concrete catalyst is interim Phase 2b data for ARS-2, the company's needle-free epinephrine candidate being studied in chronic spontaneous urticaria breakthrough flares, expected in Q1 2027. That readout will determine whether the pipeline beyond neffy can support a broader growth narrative.
Mentioned: SPRY